Skip to main content

BGNE

Stock

BGNE

Stock
Health Care
Biotechnology

Performance overview

BGNE Price
Price Chart

Forward-looking statistics

Beta
0.92
Risk
45.37%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib.

Company info

SectorHealth Care
IndustryBiotechnology
Employees8K
Market cap$16.3B

Fundamentals

Enterprise value—
Revenue—
Revenue per employee—
Profit margin—
Debt to equity—

Security info

ExchangeNASDAQ
Type of shareADR
Earnings per share (EPS)—
Dividend per share—
Revenue per share—
Avg trading volume (30 day)—
Avg trading volume (10 day)—
Put-call ratio—

Macro factor sensitivity

Growth-0.1
Credit+3.3
Liquidity+0.2
Inflation-3.9
Commodities-0.7
Interest Rates-0.1

Valuation

Dividend yield0.00%
PEG Ratio—
Price to sales—
P/E Ratio-143.19
Enterprise Value to Revenue—
Price to book—

Upcoming events

Next earnings day—
Next dividend day—
Ex. dividend day—

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free